This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Cognition Therapeutics’s 8K filing here.
Cognition Therapeutics Company Profile
Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.
See Also
- Five stocks we like better than Cognition Therapeutics
- What Do S&P 500 Stocks Tell Investors About the Market?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- Canadian Penny Stocks: Can They Make You Rich?
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Time to Load Up on Home Builders?
